Rapamycin enhances TNF-α-induced secretion of IL-6 and IL-8 through suppressing PDCD4 degradation in orbital fibroblasts

Current Eye Research

Volumn 38, Issue 6, 2013, Pages 699-706

  Lee, Won Mo ^a   Paik, Ji Sun ^a   Cho, Won Kyung ^b   Oh, Eun Hye ^c   Lee, Seong Beom ^c   Yang, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

IL 6; IL 8; MTOR; Orbital fibroblasts; PDCD4; Rapamycin; TNF

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; PROGRAMMED CELL DEATH 4; RAPAMYCIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE RELEASE; DOWN REGULATION; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ORBIT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ADIPOSE TISSUE; ADULT; APOPTOSIS REGULATORY PROTEINS; FEMALE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; ORBIT; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIROLIMUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877633820     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.750368     Document Type: Article

References (30)

1. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362: 726-738.
2. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profi les in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000; 85: 1194-1199. (Pubitemid 32269371)
3. Gu LQ, Jia HY, Zhao YJ, Liu N, Wang S, Cui B et al. Association studies of interleukin-8 gene in Graves' disease and Graves' ophthalmopathy. Endocrine 2009; 36: 452-456.
4. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995; 17: 103-108.
5. van Steensel L, Dik WA. The orbital fi broblast: a key player and target for therapy in graves' ophthalmopathy. Orbit 2010; 29: 202-206.
6. van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW et al. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fi broblasts in Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2010; 51: 1002-1007.
7. Chang S, Perry JD, Kosmorsky GS, Braun WE. Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy. Ophthal Plast Reconstr Surg 2007; 23: 225-226. (Pubitemid 46801961)
8. Bahn YS, Xue C, Idnurm A, Rutherford JC, Heitman J, Cardenas ME. Sensing the environment: lessons from fungi. Nat Rev Microbiol 2007; 5: 57-69. (Pubitemid 44942304)
9. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2: 222-232.
10. Lankat-Buttgereit B, Gete R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 2009; 101: 309-317.
11. Hillard A, Hillard B, Zheng SJ, Sun H, Miwa T, Song W, et al. Translational regulation of autoimmune infl ammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102. (Pubitemid 44846328)
12. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinfl ammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147.
13. Lankat-Buttgereit B, Maler S, Schmidt H, Parhofer KG, Gress TM, Gete R. Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol Cell 2008; 100: 703-715.
14. Yasuda M, Irie K, Murakami A. Inhibition by genistein of the lipopolysaccharide-induced down-regulation of programmed cell death 4 in RAW 264.7 mouse macrophages. Biosci Biotechnol Biochem 2010; 74: 1095-1097.
15. Young MR, Santhanam AN, Yoshikawa N, Colburn NH. Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue? Mol Interv 2010; 10: 76-79.
16. Schmid T, Bajer MM, Blees JS, Eifl er LK, Milke L, Rusamen D et al. Infl ammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis 2011; 32: 1427-1433.
17. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1-subpopulations exhibit distinct phenotypes. Eur J Immunol 2002; 32: 477-485. (Pubitemid 34173339)
18. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fi broblast subsets defi nes myofi broblastic or lipofi broblastic phenotypes. Am J Pathol 2003; 163: 1291-1300. (Pubitemid 37175078)
19. Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fi broblasts of patients with Graves' ophthalmopathy. Thyroid 2008; 18: 1291-1296.
20. Gete A, Gete R, Knolle A, Trusheim H, Schmidt H, Wilmen A et al. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun 2002; 297: 78-82.
21. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003; 23: 26-37. (Pubitemid 36008498)
22. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E et al. Programmed cell death protein 4 downregulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69: 3148-3156.
23. Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene 2001; 20: 669-676. (Pubitemid 32179335)
24. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-395. (Pubitemid 26188082)
25. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340. (Pubitemid 28385231)
26. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fi broblast growth factor beta-stimulated proliferation of endothelial cells and fi broblasts. Transplant Proc 1991; 23: 2833-2836.
27. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-417.
28. Zheng XX, Strom TB, Steele AW. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. Transplantation 1994; 58: 87-92. (Pubitemid 24224489)
29. Uthaisangsook S, Day NK, Hitchcock R, Lerner A, James-Yarish M, Good RA et al. Negative regulation of interleukin-12 production by a rapamycin-sensitive signaling pathway: a brief communication. Exp Biol Med (Maywood) 2003; 228: 1023-1027. (Pubitemid 37222170)
30. Hoentjen F, Sartor RB, Ozaki M, Jobin C. STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005; 105: 689-696. (Pubitemid 40070754)